Pazdur grills PD-1/PD-L1 companies over lack of collaboration, trial redundancies

FDA's Oncology Center of Excellence Director Richard Pazdur pressed representatives from companies with marketed PD-1/PD-L1 inhibitors to explain why they aren't collaborating more in the clinic while questioning whether there are too many of these drugs on the market. His comments came as he moderated a session at the American Association for Cancer Research (AACR) meeting on Monday titled "PD-1 Pandemonium."

Pazdur chastised companies for failing to work together to develop biomarkers and conduct

Read the full 733 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE